The Use of the Social Networking to Promote Educational and Consultative Actions Among Kidney Transplanted Adolescents.

July 18, 2017 updated by: Claudiana Briskiewski Pase, Instituto de Cardiologia do Rio Grande do Sul

The Use of the Social Networking to Promote Educational and Consultative Actions Among Kidney Transplanted Adolescents. Comparison of the Knowledge, Satisfaction and Self-esteem Between Two Groups: a Randomized Clinical Trial.

This study is designed to compare the knowledge, satisfaction and self-esteem of kidney transplanted adolescents measured through questionnaires between two groups: patients undergoing conventional treatment with no other intervention versus patients undergoing conventional treatment and receiving additional educational and consultative actions using a closed facebook group.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Based on literature, there are strong evidences that the use of social media improves the outcomes of chronic treatments. Currently, there is no study using social media as an education tool in kidney transplant patients in Brazil. This study is designed to answer the question: "Does the use of a popular social media such as facebook improves the knowledge, satisfaction and self-steem levels among kidney transplant adolescents when compared with their peers ?" This is a non-blinded randomized clinical trial. Patients will be randomly included into one of the two groups: the control group who will not receive any intervention or the facebook group (who will receive additional educational and consultative support through a closed facebook group) After three months, knowledge level, satisfaction level and self-esteem will be assessed by specific designed questionnaires and by the application of the Rosenberg's self-esteem scale. The study will have a sample of 122 subjects, equally divided (61 participants in each group). Collected data will be compared using the chi square test.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
128

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Brazil
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brazil, 90240-510
        • Hospital da Criança Santo Antônio da Santa Casa de Misericórdia

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

12 years to 21 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion criteria

  • patients receiving follow up care by the transplant interdisciplinary team either in the pre or in the post transplant period

Exclusion criteria

  • patients with chronic kidney disease not enrolled to receive a kidney transplant.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: Facebook group
Patients of the kidney transplantation group randomly assigned to be part of a closed facebook group.
Behavioral: Facebook group
A closed facebook group used to deliver multimedia content specifically produced to inform the participants about chronic kidney disease, kidney transplantation and related topics. This group is also used to share doubts and life experiences among participants and the interdisciplinary team.
No Intervention: Control group
Patients of the kidney transplantation group that do not receive specific educational interventions.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Knowledge about the disease
Time Frame: 3 months
Knowledge about the disease and associated conditions measured by a specific designed questionnaire.
3 months
Satisfaction about the treatment
Time Frame: 3 months
Satisfaction with the interdisciplinary team obtained by a specific designed questionnaire
3 months
Self-esteem
Time Frame: 3 months
Assessment of the participant's self-esteem through the application of the "Rosenberg's Self-Esteem Scale"
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Instituto de Cardiologia do Rio Grande do Sul

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Irmandade Santa Casa de Misericórdia de Porto Alegre

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Silvia Goldmeier, PhD, Fundação Instituto de Cardiologia

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

  • Sesso, R. Epdemiologia da doença renal crônica no Brasil. Guia de Nefrologia. São Paulo: Manole; 2002.
  • Garcia, VD, Pacheco, L. Revista Brasileira de transplantes: Dimensionamento dos transplantes no Brasil e em cada estado. Ano XX n. 4. 2014.
  • Lira ALBC, Guedes MVC, Lopes MVO. Adaptação psicossocial do adolescente pós-transplante renal segundo a teoria de roy. Invest Educ Enferm. 2005; 23;1: 68-77.
  • Morales LC, Castilho E. Vivencias de los(as) adolescentes en diálisis: una vida con múltiples pérdidas pero con esperanza. Colombia Médica. 2007; 38; 4: 44-53.
  • Pereira L M. Adesão ao tratamento imunossupressor no transplante renal. São Paulo: Permanyer Brasil Publicações, Ltda; 2012.
  • Garcez JLAF, Maciel FR, Cardoso VMB. Considerações ergonômicas para aplicação de mídia em ambientes educacionais para crianças de ensino fundamental. Produção. 2012; 22; 2: 284-295.
  • Vitola, SP. Transplante renal em crianças com peso inferior a 15 Kg; acesso cirúrgico extraperitoneal- Experiência em 62 transplantes. [Tese]. Porto Alegre: Pós-graduação em Ciências Cirúgicas da Faculdade de Medicina da Universidade Federal do Rio Grande do Sul, 2011.
  • Casas RV. Transplante renal pediátrico. Enero, 2003; 59; 1460, 24-30.
  • Garcia CD, Bittencourt VB, Rohde RW, Vitola SP. Transplante renal pediátrico. in: Garcia CD, Pereira JD, Zago MK, Garcia VD. Manual de doação e transplantes. 1.ed. Rio de Janeiro: Elsevier; 2013. p. 225-234.
  • Goldani JC, Vitola SP, Souza LV, Souza LVB. Transplante renal. In: Garcia CD, Pereira JD, Zago MK, Garcia VD. Manual de doação e transplantes. 1.ed, Rio de Janeiro: Elsevier; 2013. p. 193-198.
  • Matas AJ. Impacto de não-adesão do receptor nos desfechos em longo prazo de transplante. Revisão da literatura e experiência da universidade de Minnesola. Bras. Transpl. 2007; 828-831.
  • Nifa S, Rudnicki T. Depressão em pacientes Renais Crônicos em tratamento de Hemodiálise. Rev SBPH. 2010; 13; 1.
  • Brasil, Secretaria da Saúde. Manual de atenção à saúde do adolescente/ Secretaria da Saúde. Coordenação de Desenvolvimento de Programas e Políticas de Saúde- CODEPPS. São Paulo: SMS, 2006. 328p
  • Marciano RC. Transtornos mentais e qualidade de vida em crianças e adolescentes com doença renal crônica em seus cuidadores.[dissertação]. Minas Gerais: Pós-graduação da Faculdade de Medicina da UFMG, 2009.
  • Christensen CM. Inovação na gestão da saúde: soluções disruptivas para reduzir custos e aumentar qualidade. Porto Alegre: Bookman, 2009. 422p.
  • Stoltz T. Mídia, cognição e educação. Educar. 2005; 26; 147-156.
  • Garcez JLAF, Maciel FR, Cardoso VMB. Considerções ergonômicas para aplicação de mídia em ambientes educacionais para crianças de ensino fundamental. Produção. 2012; 22; 2. 284-295.
  • Lenhart A. Teens and Mobile Phones. Pew Internet & American Life Project. 2010.
  • Nielsen. Social media comes of age. Retrieved May 2 2013 from <http://www.nielsen.com/us/en/newswire/2012/social-media-report-2012-social-media-comes-of-age.html>.
  • Barbosa SM, Dias FLA, Pinheiro AKB, Pinheiro PNC, Vieira NFC. Jogo educativo como estratégia de educação em saúde para adolescentes na prevenção às DST/AIDS. Rev. Eletr. Enf. 2010; 12; 2. 337-41.
  • Ellison N, Steinfield C, Lampe C. The Benefits of Facebook ''Friends:'' Social Capital and College Students' Use of Online Social Network Sites. Journal of Computer-Mediated Communication. 2007; 12. 1143-1168.
  • Brasil. Ministério da Saúde. Conselho Nacional de Saúde. Resolução 196/96, de 10 de Outubro de 1996. Dispõe sobre as diretrizes e normas regulamentadoras de pesquisa envolvendo seres humanos. Brasília, 1996.
  • Gamonar F. A morte dos Shoppings, o fim do fecebook e o futuro criado pelos millennials. 2015. https://www.linkedin.com/pulse/morte-dos-shoppings-o-fim-do-facebook-e-futuro-criado-flavia-gamonar. Visualizado dia: 14/02/16.
  • Carmo EH, Barreto ML, Silva JBJ. Mudanças nos padrões de morbimortalidade da populaçãoo brasileira: os desafios para um novo século. Epidemiol. Serv. Saúde. 2003; 12. 2. 63-75.
  • Randomization.com [internet]. Available in:http:// www.randomization.com
  • Dini GM, Quaresma MR, Ferreira LM. Adaptação cultural e validaçãoo da versão Brasileira da Escala de Auto-estima de Rosenberg.Rev. Soc. Bras. Cir. Plast. 2004; 19. 1. 41-52.
  • Rosenberg M. Society and the adolescente self image. Princeton: Princeton university Press; 1965.
  • Noronha IL, Ferraz AS, Silva AP Filho, Saitovich D, Carvalho DBM, Paula FJ, Campos H, Lanhez LE, Garcia VD. Transplante Renal: Doador e Receptor. Projeto Diretrizes Associação Médica Brasileira e Conselho Federal de Medicina. 1-19.
  • Oliva M, Singh TP, Gauvreau K, Vanderpluym CJ, Bastardi HJ, Almond CS. Impact of medication non-adherence on survival after pediatric heart transplantation in the U.S.A. J Heart Lung Transplant. 2013 Sep;32(9):881-8. doi: 10.1016/j.healun.2013.03.008. Epub 2013 Jun 4.
  • Takemoto SK, Pinsky BW, Schnitzler MA, Lentine KL, Willoughby LM, Burroughs TE, Bunnapradist S. A retrospective analysis of immunosuppression compliance, dose reduction and discontinuation in kidney transplant recipients. Am J Transplant. 2007 Dec;7(12):2704-11. doi: 10.1111/j.1600-6143.2007.01966.x. Epub 2007 Sep 14.
  • Pase C, Mathias AD, Garcia CD, Garcia Rodrigues C. Using Social Media for the Promotion of Education and Consultation in Adolescents Who Have Undergone Kidney Transplant: Protocol for a Randomized Control Trial. JMIR Res Protoc. 2018 Jan 9;7(1):e3. doi: 10.2196/resprot.8065.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 1, 2016

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 1, 2016

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 1, 2016

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
September 19, 2016

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 9, 2017

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 12, 2017

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 21, 2017

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 18, 2017

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2017

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 5259/16

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

IPD Plan Description

No IPD will be shared among other researchers.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Kidney Transplantation

Clinical Trials on Facebook group

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings